Levenson Victor V
Robert H. Lurie Comprehensive Cancer Center, Feinberg School of Medicine, Northwestern University, 710 N. Fairbanks Ct., Olson, 8-424, Chicago, IL 60611, USA.
Biochim Biophys Acta. 2007 Jun;1770(6):847-56. doi: 10.1016/j.bbagen.2007.01.017. Epub 2007 Feb 12.
Early detection of breast cancer reduces the suffering and cost to society associated with the disease. A sensitive assay to identify biomarkers that can accurately diagnose the onset of breast cancer using non-invasively collected clinical specimens is ideal for early detection. The earlier and more accurate the diagnostic biomarker can predict disease onset, the more valuable it becomes. Here, a brief review of existing and emerging approaches for breast cancer biomarker identification and analysis is presented. Those biomarkers found in biological fluids, blood in particular, apparently hold the best promise for fast development of screening assays. Autoantibodies and abnormal tumor-specific DNA methylation found in cell-free plasma DNA may provide the best opportunity for constructing multiplexed and highly redundant tests, which will be sufficiently specific and sensitive for early detection of breast cancer. It is expected that technologies developed for breast cancer detection will be useful for other types of cancer.
乳腺癌的早期检测可减轻与该疾病相关的社会痛苦和成本。一种能够使用非侵入性采集的临床标本准确诊断乳腺癌发病的生物标志物的灵敏检测方法,对于早期检测来说是理想的。诊断生物标志物预测疾病发病越早、越准确,其价值就越大。在此,对乳腺癌生物标志物识别和分析的现有及新兴方法进行简要综述。那些在生物体液,尤其是血液中发现的生物标志物,显然最有希望快速开发出筛查检测方法。游离血浆DNA中发现的自身抗体和异常肿瘤特异性DNA甲基化,可能为构建多重且高度冗余的检测提供最佳机会,这些检测对于乳腺癌的早期检测将具有足够的特异性和敏感性。预计为乳腺癌检测开发的技术将对其他类型的癌症有用。